Financings in Brief: Angeion
This article was originally published in The Gray Sheet
Executive SummaryAngeion: Files registration statement with Securities and Exchange Commission for a direct placement, principally to selected institutional investors, of 2.5 mil. shares of common stock. Proceeds will go toward R&D, clinical trials, capital equipment, leasehold improvements and general corporate purposes, the Minneapolis-based firm says. Stock in Angeion has recently been trading in the $4-6 range. The firm is developing the Sentinel implantable cardioverter defibrillator and catheter ablation systems. The offering follows a direct placement of 4.9 mil. securities last fall ("The Gray Sheet" Oct. 10, 1994, p. 20). Raymond James & Associates is placement agent for the offering...
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.